Product ID |
Product Name |
CAS# |
Purity |
Y3310889 |
IHVR-17028 |
1428247-78-2 |
97% |
Y3285827 |
PI3K/AKT-IN-1 |
3033069-84-7 |
99.62% |
Y3178945 |
NS2B/NS3-IN-3 hydrochloride |
2832876-91-0 |
98.00% |
Y3177168 |
Monomethyl auristatin E intermediate-14 |
1932791-56-4 |
95% |
Y3177169 |
Immunoproteasome inhibitor 1 |
2755772-63-3 |
99.59% |
Y3171549 |
ARN25068 |
2649882-80-2 |
99.66% |
Y3174582 |
HDAC1/2-IN-3 |
2121516-17-2 |
98.05% |
Y3144806 |
Transketolase-IN-1 |
2763650-87-7 |
99.06% |
Y3286052 |
ABD957 |
3007772-60-0 |
99.46% |
Y3144850 |
BODIPY FL-DHPE |
217075-07-5 |
95.0% |
Y3145141 |
(R,R)-CPI-1612 |
2374972-35-5 |
99.49% |
Y3171165 |
FAK-IN-2 |
2872588-02-6 |
98.27% |
Y3178816 |
GPX4-IN-2 |
2485005-22-7 |
98.66% |
Y3173009 |
DHX9-IN-2 |
2973395-71-8 |
95% |
Y3171166 |
Senexin C |
2375554-02-0 |
98.06% |
Y3144915 |
H4R antagonist 3 |
1003091-20-0 |
95% |
Y3144876 |
Cyclophellitol aziridine |
136861-97-7 |
95.0% |
Y3144879 |
Ionizable lipid-1 |
2055939-68-7 |
98.0% |
Y3144882 |
Glucose-malemide |
2093979-63-4 |
99.72% |
Y3289994 |
Trifluoromethyl-tubercidin |
1854086-05-7 |
98% |
Y3171538 |
hPL-IN-2 |
24900-61-6 |
98.17% |
Y3175833 |
h-NTPDase-IN-4 |
2939933-09-0 |
98.64% |
Y3291506 |
Firefly luciferase-IN-1 |
2765796-41-4 |
98% |
Y3173432 |
PP5-IN-1 |
1022417-69-1 |
99.20% |
Y3171583 |
Tubulin polymerization-IN-47 |
2834087-62-4 |
99.51% |
Y3181135 |
SMD-3040 intermediate-2 |
2632308-00-8 |
95.82% |
Y3171737 |
TMX-4153 |
2867519-91-1 |
98.96% |
Y3173445 |
TH-Z145 |
2260887-57-6 |
95.50% |
Y3175474 |
WAY-639872 |
796119-18-1 |
98.0% |
Y3306105 |
DB008 |
2991637-98-8 |
98% |
Y3176901 |
PM-43I |
1637532-77-4 |
99% |
Y3178671 |
EIF2a activator 1 |
2851820-52-3 |
98% |
Y3177049 |
CB1R Allosteric modulator 3 |
2633686-36-7 |
95% |
Y3171372 |
SDH-IN-2 |
1823354-06-8 |
99% |
Y3292788 |
4,5-Dibromo-2-nitro-1H-imidazole |
121816-77-1 |
95% |
Y3290563 |
Dimethyl 5-hydroxy-2,4,6-triiodoisophthalate |
19928-65-5 |
95% |
Y3295008 |
di-tert-butyl 6,6-difluoro-1,4-diazepane-1,4-dicarboxylate |
2648649-11-8 |
95% |
Y3286973 |
6,6-difluoro-1,4-bis(toluene-4-sulfonyl)-[1,4]diazepane |
529509-59-9 |
95% |
Y3287950 |
tert-butyl 4-(3-phenoxypropyl)piperazine-1-carboxylate |
1384256-96-5 |
95% |
Y3293533 |
N - (cis 4-methoxycyclohexyl) carbamate tert butyl ester |
1854974-17-6 |
95% |
Y3295143 |
Pyridazine, 4-bromo-6-chloro-3-iodo |
1823876-05-6 |
95% |
Y3298165 |
3-ethynyl-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}azetidine-3-carboxylic acid |
2386218-24-0 |
95% |
Y3295740 |
tert-butyl N-(5-bromo-2-fluoro-3-iodophenyl)carbamate |
2680776-90-1 |
95% |
Y3181092 |
6-chloropyridine-3-sulfinamide |
2710998-74-4 |
95% |
Y3309475 |
2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid |
2703764-14-9 |
95% |
Y3295315 |
2-phenyloxolane-2-carbaldehyde |
1469994-91-9 |
95% |
Y3290292 |
rac-(2R,3R)-3-phenyl-1-(prop-2-enoyl)azetidine-2-carboxylic acid, trans |
2866323-11-5 |
95% |
Y3294689 |
Nicotinamide-13C6 |
2749910-55-0 |
95% |
Y3286928 |
FAK-IN-10 |
491839-65-7 |
98% |
Y3297921 |
PROTAC CDK9 degrader-7 |
2935587-90-7 |
99% |
Y3297643 |
PB131 |
2924425-63-6 |
99% |
Y3313079 |
M4K2234 |
2421141-51-5 |
98% |
Y3309878 |
CDK8-IN-12 |
2613307-67-6 |
98% |
Y3305860 |
ATG7-IN-1 |
2226229-87-2 |
100% |
Y3307181 |
Propargyl-PEG4-GGFG-DXd |
2762518-94-3 |
99% |
Y3297873 |
Val-Cit-PAB-OSBT |
2210262-26-1 |
99% |
Y3307387 |
DHX9-IN-1 |
2973747-89-4 |
98% |
Y3290192 |
CDK8-IN-11 |
2839338-28-0 |
98% |
Y3291503 |
Amine-PEG3-Lys(PEG3-N3)-PEG3-N3 |
2244602-35-3 |
98% |
Y3295408 |
GGFG-amide-glycol-amide-Exatecan |
2866301-18-8 |
98% |
Y3308468 |
RIPK1-IN-9 |
2682889-57-0 |
98% |
Y3171493 |
WAY-327131 |
725695-33-0 |
98% |
Y3177587 |
PRMT5-IN-30 |
330951-01-4 |
95% |
Y3293541 |
BAY 1892005 |
2036352-13-1 |
99% |
Y3294164 |
(R)-FT709 |
2413991-75-8 |
97% |
Y3175760 |
4'-Methyl-ß-naphthoflavone |
1282513-75-0 |
99% |
Y3293807 |
Cisd2 agonist 1 |
2916371-54-3 |
99% |
Y3289656 |
Val-Cit-amide-Cbz-N(Me)-Maytansine |
1628543-59-8 |
97% |
Y3181347 |
WAY-313318 |
351993-88-9 |
98% |
Y3190714 |
CGP78850 |
258326-83-9 |
99% |
Y3296689 |
WAY-659590 |
867283-39-4 |
98% |
Y3287719 |
PI5P4Ks-IN-2 |
2766854-03-7 |
99% |
Y3288372 |
Dilaurylglycerosulfate sodium |
99388-09-7 |
99% |
Y3287995 |
GFP16 |
749212-56-4 |
95% |
Y3219254 |
PqsR/LasR-IN-1 |
924818-33-7 |
98% |
Y3285984 |
MNG-14a |
1257853-50-1 |
95% |
Y3290083 |
GPR52 receptor modulator 1 |
2642079-89-6 |
99% |
Y3286598 |
PDS-MMAE |
1613113-44-2 |
99% |
Y3215892 |
(R)-Necrocide 1 |
1247028-62-1 |
99% |
Y3293675 |
RGB-1 |
930455-91-7 |
98% |
Y3214511 |
Methyl carbamate-d3 |
124522-32-3 |
98% |
Y3285997 |
BODIPY-581/591 NHS ester |
150152-70-8 |
99% |
Y3315643 |
Dyrk1A-IN-3 |
2493976-27-3 |
99% |
Y3285755 |
PROTAC Her3 Degrader-8 |
2103331-95-7 |
99% |
Y3307317 |
YW2036 |
2131223-92-0 |
100% |
Y3290256 |
Palazestrant |
2092925-89-6 |
98% |
Y3294309 |
Cy7.5 NHS ester |
2708152-94-5 |
96% |
Y3309811 |
Estrogen receptor ß antagonist 2 |
2580941-14-4 |
95% |
Y3289729 |
V-0219 hydrochloride |
2922283-73-4 |
99% |
Y3305667 |
MAO-B-IN-9 |
2416910-88-6 |
99% |
Y3296510 |
JS25 |
2411771-95-2 |
98% |
Y3295202 |
Anti-inflammatory agent 51 |
2911610-03-0 |
98% |
Y3292085 |
Thalidomide-5-PEG3-NH2 hydrochloride |
2761385-81-1 |
97% |
Y3295780 |
hCAIX-IN-18 |
2925261-76-1 |
98% |
Y3298132 |
Thalidomide-5-O-C5-NH2 hydrochloride |
2761385-94-6 |
95% |
Y3296175 |
Pomalidomide-5-C10-NH2 hydrochloride |
2863635-00-9 |
95% |
Y3293757 |
Propidium monoazide |
91416-20-5 |
99% |
Y3290586 |
MAO-B-IN-17 |
2890188-81-3 |
99% |
Y3289623 |
TH470 |
2834739-51-2 |
99% |
Y3305213 |
11ß-HSD1-IN-11 |
859721-81-6 |
99% |